Only 4 of 100 women with early-stage invasive breast cancer benefit from chemotherapy*, and its toxic nature can result in severe side effects.
Oncotype DX is the only test that can help you find out if chemotherapy is the best treatment for you—or if there is another option that might suit you better. Oncotype DX gives you personalized information about your individual breast cancer diagnosis. This can be used to help tailor treatment for your breast cancer.
The test is intended to be used for patients with early-stage, node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy.
Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, please visit: www.genomichealth.com...
* Lancet 1996 Apr 20; 347(9008):1006-71